Specific mutation in RhoA gene is associated with T-cell lymphoma cancer cells
- 總結
- Adolfo Ferrando, M.D., Ph.D.
- 技術優勢
- Current treatments are primarily chemotherapy combinations with no gene-specific targetsNovel allele associated with T-cell lymphoma provides a new target for drug therapiesHigh levels of Rho are associated with malignant cellsPatent information:Patent Pending
- 技術應用
- Clinical diagnostic for a patient's risk of T-cell lymphoma and sensitivity to RhoA inhibitorsResearch tool for better understanding of T-cell lymphomaPotential clinical target for new T-cell lymphoma therapies
- 詳細技術說明
- Adolfo Ferrando, M.D., Ph.D.
- *Abstract
-
None
- *Inquiry
- Peter GolikovColumbia Technology VenturesTel: (212) 854-8444Email: TechTransfer@columbia.edu
- *IR
- CU13221
- *Principal Investigation
-
- 國家/地區
- 美國
欲了解更多信息，請點擊 這裡
